REMARKS

On February 27, 2001, the Patent Office mailed a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. In accordance with the requirements of 37 CFR Sections 1.821-1.825, Applicants are providing herewith a substitute paper copy of the Sequence Listing, along with a computer readable form of the Sequence Listing. The sequence disclosures in the substitute Sequence Listing are fully supported by the specification as filed, and as such, do not introduce new matter. The enclosed substitute Sequence Listing includes SEQ ID NO:s 1-30 as filed in the original Sequence Listing for the application, and SEQ ID NO:s 31 and 32 have been added to recite the sequences provided in Figure 7B.

The Brief Description of the Drawings on page 7 in the specification has been amended to recite sequence identifiers, SEQ ID NO:s 31 and 32, for those sequences appearing in Figure 7B. Attached hereto is a document entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE** to illustrate these amendments to the specification.

Respectfully submitted,
GENENTECH, INC.

Date: April 4, 2001

By: Diane L. Marschang
Diane L. Marschang
Reg. No. 35,600

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5416
Fax: (650) 952-9881

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

On page 7, in the paragraph appearing on lines 8-23, the text has been amended to insert "SEQ ID NO:31" and "SEQ ID NO:32" as follows:

--- Figure 7 Domain function of TLR2 in signaling. **a.** Illustrations of various TLR2 constructs. TLR2-WT, the full-length epitope-tagged form of TLR2, TLR2-Δ1 and -Δ2 represent a truncation of 13 or 141 amino acids at the carboxyl terminus, respectively. CD4-TLR2, a human CD4-TLR2 chimera replacing the extracellular domain of TLR2 with amino acids 1-205 of human CD4. ECD, extracellular domain; TM, transmembrane region; ICD, intracellular domain. **b.** C-terminal residues critical for IL-1R (SEQ ID NO:31) and TLR2 (SEQ ID NO:32) signal transduction. Residue numbers are shown to the right of each protein. Arrow indicated the position of the TLR2-Δ1 truncation. *, residues essential for IL-1R signaling (Heguy *et al.*, J. Biol. Chem. 267, 2605-2609 [1992]; Croston *et al.*, J. Biol. Chem. 270, 16514-16517 [1995])l I, identical amino acid; :, conservative changes. **c.** TLR-R2 variants fail to induce NF-κB in response to LPS and LBP. 293 cells were transiently transfected with pGL3.ELAM.tk and expression vectors encoding full-length TLR2 or TLR2 variants as indicated. The cells were also transfected with a CD14 expression plasmid (+mCD14) or with a control plasmid (-mCD14). Equal expression of each protein is confirmed by Western blot using either anti-gD or CD4 antibody (bottom). The luciferase assay was performed as described in the Examples. Data were obtained from duplicate experiments. ---